Peptide therapy
Bremelanotide (PT-141) (Vyleesi®): what to know
Medical review pending · Last updated
Regulatory status: FDA-approved product. FDA-approved (Vyleesi®, 2019) for premenopausal women with acquired, generalized hypoactive sexual desire disorder not caused by a medical or psychiatric condition, relationship problems, or medication. Other uses are off-label and at a licensed provider's discretion.
What is Bremelanotide (PT-141)?
Bremelanotide activates melanocortin receptors in the brain involved in sexual desire. It is used as needed, not daily.
Who it may be for
Premenopausal women with HSDD, after evaluation by a licensed provider. Not for people with uncontrolled high blood pressure or known cardiovascular disease.
How it is given
Subcutaneous autoinjector, used as needed, if prescribed.
Safety considerations
- Nausea is common, especially with the first doses.
- Temporary increase in blood pressure and decrease in heart rate after each dose.
- Possible darkening of skin (focal hyperpigmentation), flushing, and headache.
- May interact with some oral medicines, including naltrexone.
Any prescription is at the sole discretion of a licensed provider after evaluation. Metabcore does not make claims that Bremelanotide (PT-141) treats, cures, or prevents any disease beyond FDA-approved labeling.
Frequently asked questions
Is PT-141 the same as Vyleesi?
Yes. PT-141 is the research name for bremelanotide, the active ingredient in Vyleesi.
Is PT-141 approved for men?
No. FDA approval is for premenopausal women with HSDD. Any other use would be off-label.
Sources
Sources are listed for reference and do not imply endorsement. Regulatory status can change; check the date above.
Other peptides
Be first to know when we launch
Care through independent licensed clinicians, starting in select states.